MDT · Medtronic plc
Price & Indicators
Up next
Metrics snapshot
Useful current figures from the complete screener profile.
AI Brief
Q1 FY27 earnings call · Sep 1, 2026TL;DR. Medtronic reported Q1 FY27 revenue of $9.8B with 13.7% organic growth well ahead of expectations and raised its FY27 organic revenue growth guidance by 50bps to 7.25%-7.75% and FY27 EPS guidance to $5.94-$6.00, while announcing new strategic investments in Cornerstone Robotics and Pi-Cardia and continued 88% growth in Cardiac Ablation Solutions.
- + Q1 revenue of $9.8B with 13.7% organic growth was roughly 200bps above the guidance midpoint and ahead of expectations
- + FY27 organic revenue growth guidance raised 50bps to 7.25%-7.75%
- + FY27 non-GAAP EPS guidance raised to $5.94-$6.00
- + FY27 operating profit expected to grow approximately 10% with operating margin expanding approximately 50bps year-over-year
- + Diabetes delivered 15% growth on strong U.S. and international performance
- − Neuromodulation lagged at 3% global growth due to ongoing SCS market softness and DBS replacement headwinds
- − FX is expected to be a roughly $50M-$150M headwind to full-year revenue
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders NeutralIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Free Cash Flow non-GAAP | $1.29B | Three months ended July 31, 2026 | — |
GAAP → non-GAAP reconciliationGAAP Net cash provided by operating activities 1.79B
-503M Additions to property, plant, and equipment
= Free Cash Flow 1.29B
|
|||
| Non-GAAP diluted EPS non-GAAP | $1.45 | Q1 FY27 | — |
| Non-GAAP net income non-GAAP | $1.86B | Q1 FY27 | — |
| Non-GAAP operating margin non-GAAP | 23.7% | Q1 FY27 | — |
| Non-GAAP operating profit non-GAAP | $2.32B | Q1 FY27 | — |
| Organic revenue growth non-GAAP | 13.7% | Q1 FY27 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Medical Devices — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
MDT
this stock
Medtronic plc
|
$113.38B | -10.2% | +8.4% | 21.8 | 1.3% |
|
ABT
Abbott Laboratories
|
$174.90B | -21.1% | +5.7% | 28.1 | 1.1% |
|
SYK
Stryker Corp
|
$104.47B | -21.6% | +11.2% | 28.2 | 2.0% |
|
BSX
Boston Scientific Corp
|
$63.59B | -54.2% | +12.5% | 17.8 | 3.2% |
|
EW
Edwards Lifesciences Corp
|
$49.74B | +1.3% | +11.5% | 49.6 | 1.6% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| MDT | -3.4% | -6.3% | -1.8% | -4.8% | -10.2% |
| SPY | -0.7% | +0.1% | +12.2% | -0.6% | +11.8% |
| vs SPY | -2.7% | -6.4% | -14.0% | -4.2% | -22.0% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.